Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Immunopathogenesis of COVID-19 and early immunomodulators

  • Lee, Kyung-Yil (The Catholic University of Korea College of Medicine) ;
  • Rhim, Jung-Woo (The Catholic University of Korea College of Medicine) ;
  • Kang, Jin-Han (The Catholic University of Korea College of Medicine)
  • Received : 2019.04.27
  • Accepted : 2019.06.17
  • Published : 2020.07.15
Download PDF
⟨ Previous Next ⟩

Abstract

The novel coronavirus disease 2019 (COVID-19) is spreading globally. Although its etiologic agent is discovered as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), there are many unsolved issues in COVID-19 and other infectious diseases. The causes of different clinical phenotypes and incubation periods among individuals, species specificity, and cytokine storm with lymphopenia as well as the mechanism of damage to organ cells are unknown. It has been suggested that in viral pneumonia, virus itself is not a direct cause of acute lung injury; rather, aberrant immune reactions of the host to the insults from viral infection are responsible. According to its epidemiological and clinical characteristics, SARS-CoV-2 may be a virus with low virulence in nature that has adapted to the human species. Current immunological concepts have limited ability to explain such unsolved issues, and a presumed immunopathogenesis of COVID-19 is presented under the protein-homeostasis-system hypothesis. Every disease, including COVID-19, has etiological substances controlled by the host immune system according to size and biochemical properties. Patients with severe pneumonia caused by SARS-CoV-2 show more severe hypercytokinemia with corresponding lymphocytopenia than patients with mild pneumonia; thus, early immunomodulator treatment, including corticosteroids, has been considered. However, current guidelines recommend their use only for patients with advanced pneumonia or acute respiratory distress syndrome. Since the immunopathogenesis of pneumonia may be the same for all patients regardless of age or severity and the critical immune-mediated lung injury may begin in the early stage of the disease, early immunomodulator treatment, including corticosteroids and intravenous immunoglobulin, can help reduce morbidity and possibly mortality rates of older patients with underlying conditions.

Keywords

References

  1. World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report-53 [Internet]. Geneva (Switzerland): World Health Organization; 2020 Mar [cited 2020 Apr 3]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200313-sitrep-53-covid-19.
  2. Deng SQ, Peng HJ. Characteristics of public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med 2020;9:E575.
  3. Park PG, Kim CH, Yoon H, Kim TS, Park CW, Kim CH. Out-of-hospital cohort treatment of coronavirus disease 2019 patients with mild symptoms in Korea: an experience from a single community treatment center. J Korean Med Sci 2020;35:e140. https://doi.org/10.3346/jkms.2020.35.e140
  4. Ciotti M, Angeletti S, Minieri M, Giovannetti M, Benvenuto D, Pascarella S, et al. COVID-19 outbreak: an overview. Chemotherapy 2020;7:1-9. https://doi.org/10.1159/000220099
  5. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, Tong S. Epidemiology of COVID-19 among children in China. Pediatrics 2020;145:e20200702. https://doi.org/10.1542/peds.2020-0702
  6. Beutler BA. TLRs and innate immunity. Blood 2009;113:1399-407. https://doi.org/10.1182/blood-2008-07-019307
  7. Matzinger P. The danger model: a renewed sense of self. Science 2002;296:301-5. https://doi.org/10.1126/science.1071059
  8. Land WG. The role of damage-associated molecular patterns in human diseases: part I promoting inflammation and immunity. Sultan Qaboos Univ Med J 2015;15:e9-e21.
  9. Thomas J, Pociute A, Kevalas R, Malinauskas M, Jankauskaite L. Blood biomarkers differentiating viral versus bacterial pneumonia aetiology: a literature review. Ital J Pediatr 2020;46:4. https://doi.org/10.1186/s13052-020-0770-3
  10. Demmler GJ, Ligon BL. Severe acute respiratory syndrome (SARS): a review of the history, epidemiology, prevention, and concerns for the future. Semin Pediatr Infect Dis 2003;14:240-4. https://doi.org/10.1016/S1045-1870(03)00056-6
  11. Hui DS, Azhar EI, Kim YJ, Memish ZA, Oh MD, Zumla A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis 2018;18:e217-27. https://doi.org/10.1016/s1473-3099(18)30127-0
  12. Park SE. Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19). Clin Exp Pediatr 2020;63:119-24. https://doi.org/10.3345/cep.2020.00493
  13. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015;1282:1-23. https://doi.org/10.1007/978-1-4939-2438-7_1
  14. de Vries RD, Mesman AW, Geijtenbeek TB, Duprex WP, de Swart RL. The pathogenesis of measles. Curr Opin Virol 2012;2:248-55. https://doi.org/10.1016/j.coviro.2012.03.005
  15. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5:536-44. https://doi.org/10.1038/s41564-020-0695-z
  16. Park WB, Kwon NJ, Choi SJ, Kang CK, Choe PG, Kim JY, et al. Virus isolation from the first patient with SARS-CoV-2 in Korea. J Korean Med Sci 2020;35:e84. https://doi.org/10.3346/jkms.2020.35.e84
  17. Vetter V, Denizer G, Friedland LR, Krishnan J, Shapiro M. Understanding modern-day vaccines: what you need to know. Ann Med 2018;50:110-20. https://doi.org/10.1080/07853890.2017.1407035
  18. Shao W, Li X, Goraya MU, Wang S, Chen JL. Evolution of influenza A virus by mutation and re-assortment. Int J Mol Sci 2017;18:1650. https://doi.org/10.3390/ijms18081650.
  19. Lee KY, Rhim JW, Kang JH. Hyperactive immune cells (T cells) may be responsible for acute lung injury in influenza virus infections: a need for early immune-modulators for severe cases. Med Hypotheses 2011;76:64-9. https://doi.org/10.1016/j.mehy.2010.08.032
  20. Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. A pathological report of three COVID-19 cases by minimally invasive autopsies. Zhonghua Bing Li Xue Za Zhi (Chinese) 2020;49:E009.
  21. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A, et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur Arch Otorhinolaryngol 2020 Apr 6 [Epub]. https://doi.org/10.1007/s00405-020-05965-1.
  22. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol 2020 Apr 10 [Epub]. https://doi.org/10.1001/jamaneurol.2020.1127.
  23. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020 March 19 [Epub]. https://doi.org/10.1016/j.kint.2020.03.005.
  24. Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020 May 13 [Epub]. https://doi.org/10.1016/S0140-6736(20)31103-X.
  25. Belhadjer Z, Meot M, Bajolle F, Khraiche D, Legendre A, Abakka S, et al. Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic. Circulation 2020 May 17 [Epub]. https://doi.org/10.1161/CIRCULATIONAHA.120.048360.
  26. Chen D, Xu W, Lei Z, Huang Z, Liu J, Gao Z, et al. Recurrence of positive SARS-CoV-2 RNA in COVID-19: a case report. Int J Infect Dis 2020;93:297-9. https://doi.org/10.1016/j.ijid.2020.03.003
  27. Pulvirenti G, Parisi GF, Giallongo A, Papale M, Manti S, Savasta S, et al. Lower airway microbiota. Front Pediatr 2019;7:393. https://doi.org/10.3389/fped.2019.00393.
  28. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell 2014;157:121-41. https://doi.org/10.1016/j.cell.2014.03.011
  29. Lee KY, Hamada H, Arvonen M. Editorial: Infection-related immunemediated diseases and microbiota. Front Pediatr 2020;8:108. https://doi.org/10.3389/fped.2020.00108.
  30. Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, et al. The gut microbiota and host health: a new clinical frontier. Gut 2016;65:330-9 https://doi.org/10.1136/gutjnl-2015-309990
  31. Lee KY. New insights for febrile urinary tract infection (acute pyelonephritis) in children. Child Kidney Dis 2016;20:37-44. https://doi.org/10.3339/jkspn.2016.20.2.37
  32. Rhim JW, Kang HM, Han JW, Lee KY. A presumed etiology of Kawasaki disease based on epidemiological comparison with infectious or immunemediated diseases. Front Pediatr 2019;7:202. https://doi.org/10.3389/fped.2019.00202
  33. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019;17:181-92. https://doi.org/10.1038/s41579-018-0118-9
  34. Zimmer C. A planet of viruses. Chicago (IL): University of Chicago Press, 2011.
  35. Heimdal I, Moe N, Kokstad S, Christensen A, Skanke LH, Nordbo SA, et al. Human coronavirus in hospitalized children with respiratory tract infections: a 9-year population-based study from Norway. J Infect Dis 2019;219:1198-206. https://doi.org/10.1093/infdis/jiy646
  36. Latif Panahi, Marzieh Amiri, Somaye Pouy. Clinical characteristics of COVID-19 infection in newborns and pediatrics: a systematic review. Arch Acad Emerg Med 2020;8:e50.
  37. Schwartz DA. An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and regnancy outcomes. Arch Pathol Lab Med 2020 Mar 17 [Epub]. https://doi.org/10.5858/arpa.2020-0901-SA.
  38. Quinn RW. Comprehensive review of morbidity and mortality trends for rheumatic fever, streptococcal disease, and scarlet fever: the decline of rheumatic fever. Rev Infect Dis 1989;11:928-53. https://doi.org/10.1093/clinids/11.6.928
  39. Kil HR, Yu JW, Lee SC, Rhim JW, Lee KY. Changes in clinical and laboratory features of Kawasaki disease noted over time in Daejeon, Korea. Pediatr Rheumatol Online J 2017;15:60. https://doi.org/10.1186/s12969-017-0192-y
  40. Rhim JW, Lee YT, Kang HM, Suh JS, Lee KY. Changes in clinical features in Henoch-Schonlein purpura during three decades: an observational study at a single hospital in Korea. Clin Rheumatol 2019;38:2811-8. https://doi.org/10.1007/s10067-019-04628-9
  41. Kim EK, Youn YS, Rhim JW, Shin MS, Kang JH, Lee KY. Epidemiological comparison of three Mycoplasma pneumoniae pneumonia epidemics in a single hospital over 10 years. Korean J Pediatr 2015;58:172-7. https://doi.org/10.3345/kjp.2015.58.5.172
  42. Wyde PR, Couch RB, Mackler BF, Cate TR, Levy BM. Effect of low- and high-passage influenza virus infection in normal and nude mice. Infect and Immun 1977;15:221-9. https://doi.org/10.1128/iai.15.1.221-229.1977
  43. Falagas ME, Koletsi PK, Baskouta E, Rafailidis PI, Dimopoulos G, Karageorgopoulos DE. Pandemic A(H1N1) 2009 influenza: review of the Southern Hemisphere experience. Epidemiol Infect 2011;139:27-40. https://doi.org/10.1017/S0950268810002037
  44. Rhim JW, Go EJ, Lee KY, Youn YS, Kim MS, Park SH, et al. Pandemic 2009 H1N1 virus infection in children and adults: a cohort study at a single hospital throughout the epidemic. Int Arch Med 2012;5:13. https://doi.org/10.1186/1755-7682-5-13
  45. Korea Centers for Disease Control and Prevention. Serologic cross-reactivity of serum samples from different age groups in Korea against a novel influenza A (H1N1) virus. Public Health Wkly Rep 2009;2:744-5.
  46. Dudareva S, Schweiger B, Thamm M, Hohle M, Stark K, Krause G, et al. Prevalence of antibodies to 2009 pandemic Influenza A (H1N1) virus in German adult population in pre- and post-pandemic period. PLoS One 2011;6:e21340. https://doi.org/10.1371/journal.pone.0021340
  47. Kim JH, Yoo HS, Lee JS, Lee EG, Park HK, Sung YH, et al. The spread of pandemic H1N1 2009 by age and region and comparison among monitoring tools. J Korean Med Sci 2010;25:1109-12. https://doi.org/10.3346/jkms.2010.25.7.1109
  48. Chen CJ, Lee PI, Chang SC, Huang YC, Chiu CH, Hsieh YC, et al. Seroprevalence and severity of 2009 pandemic influenza A H1N1 in Taiwan. PLoS One 2011;6:e24440. https://doi.org/10.1371/journal.pone.0024440
  49. Ludvigsson JF. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. Acta Paediatr 2020;109:1088-95. https://doi.org/10.1111/apa.15270
  50. Dorigo-Zetsma JW, Wilbrink B, van der Nat H, Bartelds AI, Heijnen ML, Dankert J. Results of molecular detection of Mycoplasma pneumoniae among patients with acute respiratory infection and in their household contacts reveals children as human reservoirs. J Infect Dis 2001;183:675-8. https://doi.org/10.1086/318529
  51. Choi SH, Kim HW, Kang JM, Kim DH, Cho EY. Epidemiology and clinical features of coronavirus disease 2019 in children. Clin Exp Pediatr 2020;63:125-32. https://doi.org/10.3345/cep.2020.00535
  52. Muthamilarasan M, Prasad M. Plant innate immunity: an updated insight into defense mechanism. J Biosci 2013;38:433-49. https://doi.org/10.1007/s12038-013-9302-2
  53. Cooper D, Eleftherianos I. Memory and specificity in the insect immune system: current perspectives and future challenges. Front Immunol 2017;8:539. https://doi.org/10.3389/fimmu.2017.00539
  54. Lee KY. A common immunopathogenesis mechanism for infectious diseases: the protein-homeostasis-system hypothesis. Infect Chemother 2015;47:12-26. https://doi.org/10.3947/ic.2015.47.1.12
  55. Ryter SW, Ma KC, Choi AMK. Carbon monoxide in lung cell physiology and disease. Am J Physiol Cell Physiol 2018;314:C211-27. https://doi.org/10.1152/ajpcell.00022.2017
  56. Dani JA. Neuronal nicotinic acetylcholine receptor structure and function and response to nicotine. Int Rev Neurobiol 2015;124:3-19. https://doi.org/10.1016/bs.irn.2015.07.001
  57. Patel S. Danger-associated molecular patterns (DAMPs): the derivatives and triggers of inflammation. Curr Allergy Asthma Rep 2018;18:63. https://doi.org/10.1007/s11882-018-0817-3
  58. Roh JS, Sohn DH. Damage-associated molecular patterns in inflammatory diseases. Immune Netw 2018;18:e27. https://doi.org/10.4110/in.2018.18.e27
  59. Zhu B, Zhu Q, Li N, Wu T, Liu S, Liu S. Association of serum/plasma high mobility group box 1 with autoimmune diseases: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e11531. https://doi.org/10.1097/md.0000000000011531
  60. Hernandez C, Huebener P, Schwabe RF. Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene 2016;35:5931-41. https://doi.org/10.1038/onc.2016.104
  61. Venegas C, Heneka MT. Danger-associated molecular patterns in Alzheimer's disease. J Leukoc Biol 2017;101:87-98. https://doi.org/10.1189/jlb.3MR0416-204R
  62. Lee KY. Pneumonia, acute respiratory distress syndrome, and early immune-modulator therapy. Int J Mol Sci 2017;18:388. https://doi.org/10.3390/ijms18020388.
  63. Runnstrom M, Ebied AM, Khoury AP, Reddy R. Influenza-induced rhabdomyolysis. BMJ Case Rep 2018;11:e226610. https://doi.org/10.1136/bcr-2018-226610.
  64. Wu VC, Hsueh PR, Lin WC, Huang JW, Tsai HB, Chen YM, et al. Acute renal failure in SARS patients: more than rhabdomyolysis. Nephrol Dial Transplant 2004;19:3180-2. https://doi.org/10.1093/ndt/gfh436
  65. Rubin S, Eckhaus M, Rennick LJ, Bamford CG, Duprex WP. Molecular biology, pathogenesis and pathology of mumps virus. J Pathol 2015;235:242-52. https://doi.org/10.1002/path.4445
  66. Cunningham ET Jr, Kilmartin D, Agarwal M, Zierhut M. Sympathetic ophthalmia. Ocul Immunol Inflamm 2017;25:149-51. https://doi.org/10.1080/09273948.2017.1305727
  67. Spencer R, Manivannan S, Sharouf F, Bhatti MI, Zaben M. Risk factors for the development of seizures after cranioplasty in patients that sustained traumatic brain injury: a systematic review. Seizure 2019;69:11-6. https://doi.org/10.1016/j.seizure.2019.03.014
  68. Lava SAG, Milani GP, Fossali EF, Simonetti GD, Agostoni C, Bianchetti MG. Cutaneous manifestations of small-vessel leukocytoclastic vasculitides in childhood. Clin Rev Allergy Immunol 2017;53:439-51. https://doi.org/10.1007/s12016-017-8626-3
  69. Rosenberg JH, Rai V, Dilisio MF, Agrawal DK. Damage-associated molecular patterns in the pathogenesis of osteoarthritis: potentially novel therapeutic targets. Mol Cell Biochem 2017;434:171-9. https://doi.org/10.1007/s11010-017-3047-4
  70. Youn YS, Lee KY. Mycoplasma pneumoniae pneumonia in children Korean J Pediatr 2012;55:42-7. https://doi.org/10.3345/kjp.2012.55.2.42
  71. Lee KY, Rhim JW, Kang JH. Kawasaki disease: laboratory findings and an immunopathogenesis on the premise of a "protein homeostasis system". Yonsei Med J 2012;53:262-75. https://doi.org/10.3349/ymj.2012.53.2.262
  72. Lee KY. A unified pathogenesis for kidney diseases, including genetic diseases and cancers, by the protein-homeostasis-system hypothesis. Kidney Res Clin Pract 2017;36:132-44. https://doi.org/10.23876/j.krcp.2017.36.2.132
  73. Kang HK, Kim C, Seo CH, Park Y. The therapeutic applications of antimicrobial peptides (AMPs): a patent review. J Microbiol 2017;55:1-12. https://doi.org/10.1007/s12275-017-6452-1
  74. Hutchinson JA, Burholt S, Hamley IW. Peptide hormones and lipopeptides: from self-assembly to therapeutic applications. J Pept Sci 2017;23:82-94. https://doi.org/10.1002/psc.2954
  75. Nunes AT, Annunziata CM. Proteasome inhibitors: structure and function. Semin Oncol 2017;44:377-80. https://doi.org/10.1053/j.seminoncol.2018.01.004
  76. Guo XJ, Thomas PG. New fronts emerge in the influenza cytokine storm. Semin Immunopathol 2017;39:541-50. https://doi.org/10.1007/s00281-017-0636-y
  77. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med 2008;26:711-5. https://doi.org/10.1016/j.ajem.2007.10.031
  78. Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. Proc Biol Sci 2015;282:20143085.
  79. Ygberg S, Nilsson A. The developing immune system - from foetus to toddler. Acta Paediatr 2012;101:120-7. https://doi.org/10.1111/j.1651-2227.2011.02494.x
  80. Leung CW, Chiu WK. Clinical picture, diagnosis, treatment and outcome of severe acute respiratory syndrome (SARS) in children. Paediatr Respir Rev 2004;5:275-88. https://doi.org/10.1016/j.prrv.2004.07.010
  81. Youn YS, Lee KY, Hwang JY, Rhim JW, Kang JH, Lee JS, et al. Difference of clinical features in childhood Mycoplasma pneumoniae pneumonia. BMC Pediatr 2010;10:48. https://doi.org/10.1186/1471-2431-10-48
  82. Lee KY, Hong JH, Han JW, Lee JS, Lee BC, Burgner D. Features of Kawasaki disease at the extremes of age. J Paediatr Child Health 2006;42:423-7. https://doi.org/10.1111/j.1440-1754.2006.00898.x
  83. Lau EH, Hsiung CA, Cowling BJ, Chen CH, Ho LM, Tsang T, et al. A comparative epidemiologic analysis of SARS in Hong Kong, Beijing and Taiwan. BMC Infect Dis 2010;10:50. https://doi.org/10.1186/1471-2334-10-50.
  84. Frank C, Werber D, Cramer JP, Askar M, Faber M, Heiden MA, et al, the HUS Investigation Team. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011;365:1771-80. https://doi.org/10.1056/NEJMoa1106483
  85. Kim HS, Kim JH, Shin SY, Kang YA, Lee HG, Kim JS, Lee JK, Cho B: Fatal cases of 2009 pandemic influenza A (H1N1) in Korea. J Korean Med Sci 2011;26:22-7. https://doi.org/10.3346/jkms.2011.26.1.22
  86. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020 Mar 3 [Epub]. https://doi.org/10.1007/s00134-020-05991-x.
  87. Weiskopf D, Weinberger B, Grubeck-Loebenstein B. The aging of the immune system. Transplant Int 2009;22:1041-50. https://doi.org/10.1111/j.1432-2277.2009.00927.x
  88. Petrosillo N, Cataldo MA, Pea F. Treatment options for communityacquired pneumonia in the elderly people. Expert Rev Anti Infect Ther 2015;13:473-85. https://doi.org/10.1586/14787210.2015.1021783
  89. Nickol ME, Ciric J, Falcinelli SD, Chertow DS, Kindrachuk J. Characterization of host and bacterial contributions to lung barrier dysfunction following co-infection with 2009 pandemic influenza and methicillin resistant Staphylococcus aureus. Viruses 2019;11:116. https://doi.org/10.3390/v11020116.
  90. Lee SC, Youn YS, Rhim JW, Kang JH, Lee KY. Early serologic diagnosis of Mycoplasma pneumoniae pneumonia: an observational study on changes in titers of specific-IgM antibodies and cold agglutinins. Medicine (Baltimore). 2016;95:e3605. https://doi.org/10.1097/md.0000000000003605
  91. Chan KH, Cheng VC, Woo PC, Lau SK, Poon LL, Guan Y, et al. Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63. Clin Diagn Lab Immunol 2005;12:1317-21. https://doi.org/10.1128/CDLI.12.11.1317-1321.2005
  92. Atrasheuskaya AV, Kulak MV, Neverov AA, Rubin S, Ignatyev GM. Measles cases in highly vaccinated population of Novosibirsk, Russia, 2000-2005. Vaccine 2008;26:2111-8. https://doi.org/10.1016/j.vaccine.2008.02.028
  93. Ryu JU, Kim EK, Youn YS, Rhim JW, Lee KY. Outbreaks of mumps: an observational study over two decades in a single hospital in Korea. Korean J Pediatr 2014;57:396-402. https://doi.org/10.3345/kjp.2014.57.9.396
  94. Chiotos K, Hayes M, Kimberlin DW, Jones SB, James SH, Pinninti SG, et al. Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2. J Pediatric Infect Dis Soc 2020 Apr 22:piaa045. https://doi.org/10.1093/jpids/piaa045.
  95. Ang L, Lee HW, Kim A, Lee JA, Zhang J, Lee MS. Herbal medicine for treatment of children diagnosed with COVID-19: A review of guidelines. Complement Ther Clin Pract 2020;39:101174. https://doi.org/10.1016/j.ctcp.2020.101174
  96. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020 Apr 13 [Epub]. https://doi.org/10.1001/jama.2020.6019.
  97. Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW, Heavner MS. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy 2020;40:416-37. https://doi.org/10.1002/phar.2398
  98. Cameron MJ, Bermejo-Martin, JE, Danesh A, Muller MK, Kelvin DJ. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res 2008;133:13-9. https://doi.org/10.1016/j.virusres.2007.02.014
  99. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009;374:1543-56. https://doi.org/10.1016/S0140-6736(09)61114-4
  100. Short KR, Kroeze EJ, Fouchier RA, Kuiken T. Pathogenesis of influenzainduced acute respiratory distress syndrome. Lancet Infect Dis 2014;14:57-69. https://doi.org/10.1016/S1473-3099(13)70286-X
  101. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med 2006;3:e343. https://doi.org/10.1371/journal.pmed.0030343
  102. Lansbury L, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Lim WS. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 2019;2:CD010406.
  103. Rhim JW, Lee KY, Youn YS, Kang JH, Kim JC. Epidemiological and clinical characteristics of childhood pandemic 2009 H1N1 virus infection: an observational cohort study. BMC Infect Dis 2011;11:225. https://doi.org/10.1186/1471-2334-11-225
  104. Kil HR, Lee JH, Lee KY, Rhim JW, Youn YS, Kang JH. Early corticosteroid treatment for severe pneumonia caused by 2009 H1N1 influenza virus. Crit Care 2011;15:413. https://doi.org/10.1186/cc10082
  105. Lee KY, Lee HS, Hong JH, Lee MH, Lee JS, Burgner D, Lee BC. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol 2006;41:263-8. https://doi.org/10.1002/ppul.20374
  106. Youn YS, Lee SC, Rhim JW, Shin MS, Kang JH, Lee KY. Early additional immune-modulators for Mycoplasma pneumoniae pneumonia in children: An observation study. Infect Chemother 2014;46:239-47. https://doi.org/10.3947/ic.2014.46.4.239
  107. Yang EA, Kang HM, Rhim JW, Kang JH, Lee KY. Early corticosteroid therapy for Mycoplasma pneumoniae pneumonia irrespective of used antibiotics in children. J Clin Med 2019;8:E726. https://doi.org/10.3390/jcm8050726.
  108. Lee KY. Pediatric respiratory infections by Mycoplasma pneumoniae. Expert Rev Anti Infect Ther 2008;6:509-21. https://doi.org/10.1586/14787210.6.4.509
  109. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506. https://doi.org/10.1016/s0140-6736(20)30183-5
  110. Lee KY, Rhim JW, Kang JH. Early preemptive immune modulators (corticosteroids) for severe pneumonia patients infected with SARSCoV-2. Clin Exp Pediatr 2020;63:117-8. https://doi.org/10.3345/cep.2020.00290
  111. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ: HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-4. https://doi.org/10.1016/s0140-6736(20)30628-0
  112. Beth Russell, Charlotte Moss, Anne Rigg, Mieke Van Hemelrijck. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancermedicalscience 2020;14:1023.
  113. Veronese N, Demurtas J, Yang L, Tonelli R, Barbagallo M, Lopalco P, et al. Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature. Front Med (Lausanne). 2020;7:170. https://doi.org/10.3389/fmed.2020.00170
  114. Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2015;385:1511-8. https://doi.org/10.1016/S0140-6736(14)62447-8
  115. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: A randomized clinical trial. JAMA 2015;313:677-86. https://doi.org/10.1001/jama.2015.88
  116. Jiang S, Liu T, Hu Y, Li R, Di X, Jin X, et al. Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumonia: a meta-analysis. Medicine 2019;98:e16239. https://doi.org/10.1097/md.0000000000016239
  117. Tamura A, Matsubara K, Tanaka T, Nigami H, Yura K, Fukaya T. Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect. 2008;57:223-8. https://doi.org/10.1016/j.jinf.2008.06.012
  118. Tsunoda R, Usui J, Hoshino J, Fujii T, Suzuki S, Takaichi K, et al. Corticosteroids pulse therapy and oral corticosteroids therapy for IgA nephropathy patients with advanced chronic kidney disease: results of a multicenter, large-scale, long-term observational cohort study. BMC Nephrol 2018;19:222. https://doi.org/10.1186/s12882-018-1019-x
  119. Antonio R, Silvia M. Immunosuppression drug-related and clinical manifestation of coronavirus disease 2019: a therapeutical hypothesis. Am J Transplant 2020 Apr 3 [Epub]. https://doi.org/10.1111/ajt.15905.
  120. Spezzani V, Piunno A, Iselin HU. Benign COVID-19 in an immunocompromised cancer patient; the case of a married couple. Swiss Med Wkly 2020;150:w20246.
  121. Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, et al. Use of convalescent plasma therapy in two COVID-19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci 2020;35:e149. https://doi.org/10.3346/jkms.2020.35.e149
  122. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323:1582. https://doi.org/10.1001/jama.2020.4783

Cited by

  1. Nationwide Results of COVID-19 Contact Tracing in South Korea: Individual Participant Data From an Epidemiological Survey vol.8, pp.8, 2020, https://doi.org/10.2196/20992
  2. The solution on enigmas in COVID-19: the protein-homeostasis-system hypothesis vol.63, pp.7, 2020, https://doi.org/10.5124/jkma.2020.63.7.366
  3. Comparing mortalities of the first wave of coronavirus disease 2019 (COVID-19) and of the 1918-19 winter pandemic influenza wave in the USA vol.49, pp.6, 2020, https://doi.org/10.1093/ije/dyaa186
  4. Comprehensive pathogen detection in sera of Kawasaki disease patients by high-throughput sequencing: a retrospective exploratory study vol.20, pp.1, 2020, https://doi.org/10.1186/s12887-020-02380-7
  5. COVID-19 Point-of-Care Diagnostics That Satisfy Global Target Product Profiles vol.11, pp.1, 2020, https://doi.org/10.3390/diagnostics11010115
  6. Phenotype, Susceptibility, Autoimmunity, and Immunotherapy Between Kawasaki Disease and Coronavirus Disease-19 Associated Multisystem Inflammatory Syndrome in Children vol.12, 2020, https://doi.org/10.3389/fimmu.2021.632890
  7. Could natural products modulate early inflammatory responses, preventing acute respiratory distress syndrome in COVID-19-confirmed patients? vol.134, 2020, https://doi.org/10.1016/j.biopha.2020.111143
  8. Early Confirmation of Mycoplasma pneumoniae Infection by Two Short-Term Serologic IgM Examination vol.11, pp.2, 2020, https://doi.org/10.3390/diagnostics11020353
  9. Macrolide-Resistant and Macrolide-Sensitive Mycoplasma pneumoniae Pneumonia in Children Treated Using Early Corticosteroids vol.10, pp.6, 2020, https://doi.org/10.3390/jcm10061309
  10. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma vol.13, pp.9, 2020, https://doi.org/10.3390/v13091844
  11. Exposures associated with the onset of Kawasaki disease in infancy from the Japan Environment and Children’s Study vol.11, pp.1, 2020, https://doi.org/10.1038/s41598-021-92669-z